文献速递骨质疏松与代谢性骨病

临床药师依从性管理系统实施下地舒单抗覆盖天数比例改善:正常与COVID-19期间

Improvement of proportion of days covered for denosumab under implementation of clinical pharmacist adherence management system: normal and COVID-19 period.
PubMed 文献 · Osteoporos Int · 2023-10-06

本研究建立以临床药师为主导的依从性管理系统(CPAMS),回顾性纳入2021年3月至2022年5月接受地舒单抗治疗的患者85例(干预组32例,对照组53例),比较两组覆盖天数比例(PDC)及复诊情况。结果显示干预组1年后PDC显著高于对照组,但COVID-19疫情期间干预组PDC较疫情前下降。

要点

  • 临床药师主导的CPAMS可有效提高地舒单抗依从性和骨质疏松治疗。
  • 干预组1年后PDC为0.9875(0.9025-1),显著高于对照组0.5(0.5-0.5)。
  • COVID-19疫情期间干预组PDC降至0.957(0.5-1),低于疫情前。

核心结论

  • 临床药师主导的CPAMS可有效提高地舒单抗依从性和骨质疏松治疗,但该效应在COVID-19等传染病传播期间减弱。

研究设计与样本

  • 回顾性研究,收集2021年3月至2022年5月在本院接受地舒单抗治疗的患者数据,参与CPAMS者为干预组,其余为对照组。

主要发现

  • 共纳入85例患者,干预组32例,对照组53例。
  • 1年后干预组PDC为0.9875(0.9025-1),显著高于对照组0.5(0.5-0.5)。
  • 干预组后续复诊率为93.80%,对照组无患者返回复诊。
  • 干预组及时复诊与延迟复诊比例为11:19。
  • COVID-19疫情后干预组PDC为0.957(0.5-1),低于疫情前,及时复诊与延迟复诊比例为9:13。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: We established a clinical pharmacist adherence management system (CPAMS) led by clinical pharmacists to examine whether denosumab adherence could be improved. The results showed that CPAMS could effectively improve adherence to denosumab and the treatment of osteoporosis. However, this effect weakened during the spread of infectious diseases such as COVID-19. PURPOSE: Denosumab is currently one of the drugs that can effectively reduce the risk of clinical fracture. However, as a drug requiring long-term subcutaneous injection, patient adherence to denosumab is the most important factor affecting its therapeutic efficacy. Therefore, we established a clinical pharmacist adherence management system (CPAMS) led by clinical pharmacists and examined whether denosumab adherence could be improved. METHODS: Data were collected from patients receiving denosumab in our hospital between March 2021 and May 2022. The patients who participated in the CPAMS were in the intervention group, and the rest were in the control group. We analysed the proportion of days covered (PDC) value of denosumab, distribution of subsequent visits, and proportion of patients who continued participating during the normal and coronavirus (COVID-19) periods. RESULTS: Eighty-five patients were enrolled in this retrospective study: 32 in the intervention group and 53 in the control group. The PDC values were significantly higher in the intervention group (0.9875, 0.9025-1) than in the control group (0.5, 0.5-0.5) after 1 year. The subsequent visit rate in the intervention group was 93.80%. However, none of the patients in the control group returned. In the intervention group, the ratio of timely to delayed subsequent visits was 11:19. After the COVID-19 pandemic, the PDC value of the intervention group (0.957, 0.5-1) was lower than that before COVID-19, and the ratio of timely to delayed subsequent visits was 9:13. CONCLUSIONS: Clinical pharmacist-led CPAMS could effectively improve adherence to denosumab and the treatment of osteoporosis.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Yang Q, He J, Yuan F, et al. Improvement of proportion of days covered for denosumab under implementation of clinical pharmacist adherence management system: normal and COVID-19 period. Osteoporos Int. 2023. PMID: 37801081. doi:10.1007/s00198-023-06933-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。